IL33 and asthma: Notably, the administration of IL-33/ST2-neutralizing antibodies and PAD inhibitors (e.g., YW3-56) significantly attenuated MET release, suggesting that both the IL-33/ST2 signaling axis and PAD-dependent mechanisms represent promising therapeutic targets in asthma [42].